首页> 外文期刊>Leukemia and lymphoma >Is the follicular lymphoma international prognostic index better than the international prognostic index to identify high-risk follicular lymphoma patients?
【24h】

Is the follicular lymphoma international prognostic index better than the international prognostic index to identify high-risk follicular lymphoma patients?

机译:滤泡性淋巴瘤的国际预后指标是否比国际预后指数更好地识别高危滤泡性淋巴瘤患者?

获取原文
获取原文并翻译 | 示例
           

摘要

The aims of this study are to validate follicular lymphoma international prognostic index (FLIPI) prognostic score and to compare it with the international prognostic index (IPI) in a cohort of 57 Brazilian patients. According to IPI, 24 patients (42%) were in the low-risk, 28 (49%) in the intermediate-risk, and 4 (7%) in the high-risk group. The distribution according to FLIPI was: 20 (35%) in the low-risk, 8 (14%) in the intermediate-risk, and 29 (51%) in the high-risk group. According to IPI score, median OS was not reached for the low-risk, it was 45 months for the intermediate-risk and 25 months for the high-risk group (p < 0.001). When FLIPI score was applied, median OS was not reached for the low and intermediate-risk, and was 42 months for the high-risk group (p = 0.0064). These findings suggest that: (1) FLIPI score could be validated in a Brazilian population; (2) FLIPI is more accurate than IPI to identify FL patients having worse prognosis (51%); (3) IPI seems to be a better tool for clinical decisions because it selected a smaller high-risk group (7%) having worse prognosis. In our opinion, IPI high-risk patients are the real candidates for more aggressive therapies, avoiding unnecessary over-treatment.
机译:这项研究的目的是验证滤泡性淋巴瘤国际预后指数(FLIPI)的预后评分,并将其与国际预后指数(IPI)进行比较,以研究一组57名巴西患者。根据IPI,低风险组24例(42%),中风险组28例(49%),高风险组4例(7%)。根据FLIPI的分布是:低危组为20(35%),中危组为8(14%),高危组为29(51%)。根据IPI评分,低风险未达到中位OS,中风险为45个月,高风险组为25个月(p <0.001)。当应用FLIPI评分时,低危和中危组的中位OS尚未达到,高危组为42个月(p = 0.0064)。这些发现表明:(1)可以在巴西人群中验证FLIPI评分; (2)FLIPI比IPI更准确地识别出预后较差的FL患者(51%); (3)IPI似乎是临床决策的更好工具,因为它选择了较小的高风险组(7%),预后较差。我们认为,IPI高危患者是更积极疗法的真正候选人,可避免不必要的过度治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号